MedPath

Micra Atrial Tracking Using a Ventricular Accelerometer Study

Phase 1
Completed
Conditions
Atrioventricular Conduction Block
Interventions
Device: MARVEL algorithm
Registration Number
NCT03157297
Lead Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Brief Summary

The purpose of this study is to characterize performance of the MARVEL algorithm downloaded into the MicraTM TPS to provide atrial synchronous ventricular pacing in subjects with AV block.

A sub-study will be conducted within the Marvel study, the purpose of this study is to characterize the MARVEL algorithm in patients who were enrolled in the MARVEL study, and to collect and compare the accelerometer signals and AV synchrony at a second point in time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Subject has been implanted with, or is expected to be implanted with a MicraTM TPS (Model MC1VR01), with remaining device longevity of 6 years or more.
  • Subject is ≥ 18 years old and as per required local law.
  • Subject has atrioventricular (AV) block.
  • Subject (and/or witness, as applicable per local regulations) provides signed and dated authorization and/or consent per institution and local requirements.
  • Subject is willing and able to comply with the protocol.
Exclusion Criteria
  • Subject is in atrial arrhythmia at the time of enrollment.
  • Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
  • Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to MARVEL study procedures).
  • Subject meets any exclusion criteria required by local law (age or other).

Additional criteria for the MARVEL Evolve Sub-study:

Inclusion criteria:

• Subjects in the MARVEL Sub-Study have previously been enrolled in the MARVEL main study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
EnrolledMARVEL algorithmSubjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
Primary Outcome Measures
NameTimeMethod
MARVEL Evolve SubstudyInitial 24 hour period after patient enrollment

Characterize the rate of atrioventricular synchrony provided by the MARVEL algorithm and compare the accelerometer signal amplitudes and the AV synchrony provided by the MARVEL algorithm with the data collected during the initial MARVEL procedure.

Atrioventricular synchronyInitial 24 hour period after patient enrollment

On an individual heartbeat basis, this is defined as a right ventricular paced or sensed R-wave associated with an ECG confirmed P-wave.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

Emory University Hospital

🇺🇸

Atlanta, Georgia, United States

Baptist Hospital

🇺🇸

Miami, Florida, United States

Baptist Medical Center Jacksonville

🇺🇸

Jacksonville, Florida, United States

NYU Langone Medical Center

🇺🇸

New York, New York, United States

Kepler Universitätsklinikum Med Campus III

🇦🇹

Linz, Austria

Nemocnice Na Homolce

🇨🇿

Praha 5, Czech Republic, Czechia

UZ Leuven - Campus Gasthuisberg

🇧🇪

Leuven, Belgium

Odense Universitetshospital

🇩🇰

Odense C, Denmark

Maria Cecilia Hospital

🇮🇹

Cotignola, Ravenna, Italy

Hôpital Haut-Lévêque - CHU de Bordeaux

🇫🇷

Pessac, France

Azienda Ospedaliero-Universitaria Pisana - Stabilimento di Cisanello

🇮🇹

Pisa, Italy

Institut Jantung Negara

🇲🇾

Kuala Lumpur, Malaysia

Hospital Universitari Clínic de Barcelona

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath